Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw strong trading volume on Wednesday . 36,707 shares traded hands during trading, an increase of 2% from the previous session's volume of 35,954 shares.The stock last traded at $12.02 and had previously closed at $12.26.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on TLX. Wedbush reaffirmed an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. HC Wainwright began coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 target price for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th.
Check Out Our Latest Report on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Down 2.5%
The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. The firm has a 50-day simple moving average of $15.89 and a 200 day simple moving average of $16.85.
Hedge Funds Weigh In On Telix Pharmaceuticals
Several large investors have recently modified their holdings of the stock. Pier Capital LLC bought a new stake in Telix Pharmaceuticals in the 2nd quarter worth about $3,037,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $297,000. Blair William & Co. IL bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $217,000. ABC Arbitrage SA bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter valued at about $451,000. Finally, Private Advisor Group LLC bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter valued at about $170,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
